Vinva Investment Management Ltd Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Vinva Investment Management Ltd grew its position in shares of Pfizer Inc. (NYSE:PFE) by 43.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 277,023 shares of the biopharmaceutical company’s stock after buying an additional 83,558 shares during the quarter. Vinva Investment Management Ltd’s holdings in Pfizer were worth $7,319,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the 4th quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.0 %

PFE opened at $26.31 on Wednesday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $149.09 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.61. The stock’s 50 day moving average price is $26.21 and its 200 day moving average price is $27.09.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the firm earned $0.10 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.